Top Stories
Updated Phase I/II results point to durable benefit with first-line chemotherapy combination.
Arcera gains exclusive rights across emerging markets, including Latin America and the Middle East.
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
In conjunction with the move, nChroma Bio will undertake a restructuring, which news sources suggested will cut the biotech's workforce by around half.
The reported interest comes as new CEO Belén Garijo looks to bolster the French pharma's pipeline through larger M&A deals.
Conference News
48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 patients with platinum-resistant/refractory ovarian cancer 36% ORR wit...
From early antibody hits to engineered formats and antibody–oligonucleotide conjugates, Tsingke helps R&D teams generate the data they need to make the next development decision.LISBON, Portugal, Nov....
Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmac...
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 stud...
Company to Host In-Person Event at ASH 2026 Featuring New Market Research and a Physician Panel Discussion on Barriers to CAR T Access, Community Adoption in Large B-Cell Lymphoma (LBCL), and the Pote...



